MedPageToday -- The novel reversible antiplatelet agent ticagrelor (Brilinta) was associated with lower mortality from coronary artery bypass graft surgery (CABG) compared with standard clopidogrel (Plavix), according to a subanalysis of the pivotal PLATO trial.
